To determine its clinical relevance, we quantified SET in a series of 231 CRC patients without metastatic disease at diagnosis, observing that SET overexpression is a common alteration that is associated with relapse and predicts shorter overall survival and time to metastasis. Here, SET is linked to metastatic neoplasm.